Cigna has filed a lawsuit against Bristol Myers Squibb, accusing the pharmaceutical giant of violating federal antitrust law. The lawsuit alleges that Bristol Myers Squibb maintained an illegal monopoly over its blockbuster multiple myeloma drug, Pomalyst, by preventing generic versions from entering the market.
This legal action by Cigna targets practices that it claims keep drug prices artificially high, impacting its ability to secure affordable medications for its members and clients. The outcome of this antitrust suit could have significant implications for drug pricing and competition within the pharmaceutical industry.
For Cigna, challenging such alleged monopolies aligns with its stated goals of driving affordability and value in healthcare, particularly through its Evernorth Health Services segment. A favorable ruling could lead to lower drug costs, benefiting Cigna's PBM business and its customers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.